In cases where the primary treatment for ovarian cancer involves a combination of surgery and chemotherapy, which is usually the standard of care, the decrease in CA-125 levels may not directly indicate the response to chemotherapy because the decline in CA-125 levels is a result of both treatment modalities working in tandem [19]. This evidence concerns the gene MUC16 and ovarian carcinoma.